A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR

被引:30
作者
Kaiser, M. F. [1 ,2 ]
Walker, B. A. [1 ]
Hockley, S. L. [1 ]
Begum, D. B. [1 ]
Wardell, C. P. [1 ]
Gonzalez, D. [1 ]
Ross, F. M. [3 ]
Davies, F. E. [1 ]
Morgan, G. J. [1 ]
机构
[1] Inst Canc Res, Div Mol Pathol, Haematooncol Res Unit, London SW3 6JB, England
[2] Charite, Dept Haematol & Oncol, D-13353 Berlin, Germany
[3] Univ Southampton, Wessex Reg Genet Lab, Salisbury, Wilts, England
关键词
EXPRESSION; TRIAL; CKS1B; FGFR3; IX;
D O I
10.1038/leu.2013.12
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:1754 / 1757
页数:4
相关论文
共 13 条
[1]   A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression [J].
Annunziata, Christina M. ;
Hernandez, Lidia ;
Davis, R. Eric ;
Zingone, Adriana ;
Lamy, Laurence ;
Lam, Lloyd T. ;
Hurt, Elaine M. ;
Shaffer, Arthur L. ;
Kuehl, W. Michael ;
Staudt, Louis M. .
BLOOD, 2011, 117 (08) :2396-2404
[2]   Molecular pathogenesis and a consequent classification of multiple myeloma [J].
Bergsagel, PL ;
Kuehl, WM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (26) :6333-6338
[3]   Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma [J].
Bergsagel, PL ;
Kuehl, WM ;
Zhan, FH ;
Sawyer, J ;
Barlogie, B ;
Shaughnessy, J .
BLOOD, 2005, 106 (01) :296-303
[4]   A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial [J].
Boyd, K. D. ;
Ross, F. M. ;
Chiecchio, L. ;
Dagrada, G. P. ;
Konn, Z. J. ;
Tapper, W. J. ;
Walker, B. A. ;
Wardell, C. P. ;
Gregory, W. M. ;
Szubert, A. J. ;
Bell, S. E. ;
Child, J. A. ;
Jackson, G. H. ;
Davies, F. E. ;
Morgan, G. J. .
LEUKEMIA, 2012, 26 (02) :349-355
[5]   FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies [J].
Chen, J ;
Lee, BH ;
Williams, IR ;
Kutok, JL ;
Mitsiades, CS ;
Duclos, N ;
Cohen, S ;
Adelsperger, J ;
Okabe, R ;
Coburn, A ;
Moore, S ;
Huntly, BJP ;
Fabbro, D ;
Anderson, KC ;
Griffin, JD ;
Gilliland, DG .
ONCOGENE, 2005, 24 (56) :8259-8267
[6]   Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma [J].
Fonseca, R. ;
Van Wier, S. A. ;
Chng, W. J. ;
Ketterling, R. ;
Lacy, M. Q. ;
Dispenzieri, A. ;
Bergsagel, P. L. ;
Rajkumar, S. V. ;
Greipp, P. R. ;
Litzow, M. R. ;
Price-Troska, T. ;
Henderson, K. J. ;
Ahmann, G. J. ;
Gertz, M. A. .
LEUKEMIA, 2006, 20 (11) :2034-2040
[7]   International Myeloma Working Group molecular classification of multiple myeloma: spotlight review [J].
Fonseca, R. ;
Bergsagel, P. L. ;
Drach, J. ;
Shaughnessy, J. ;
Gutierrez, N. ;
Stewart, A. K. ;
Morgan, G. ;
Van Ness, B. ;
Chesi, M. ;
Minvielle, S. ;
Neri, A. ;
Barlogie, B. ;
Kuehl, W. M. ;
Liebisch, P. ;
Davies, F. ;
Chen-Kiang, S. ;
Durie, B. G. M. ;
Carrasco, R. ;
Sezer, Orhan ;
Reiman, Tony ;
Pilarski, Linda ;
Avet-Loiseau, H. .
LEUKEMIA, 2009, 23 (12) :2210-2221
[8]   In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression [J].
Keats, JJ ;
Reiman, T ;
Maxwell, CA ;
Taylor, BJ ;
Larratt, LM ;
Mant, MJ ;
Belch, AR ;
Pilarski, LM .
BLOOD, 2003, 101 (04) :1520-1529
[9]   The genetic architecture of multiple myeloma [J].
Morgan, Gareth J. ;
Walker, Brian A. ;
Davies, Faith E. .
NATURE REVIEWS CANCER, 2012, 12 (05) :335-348
[10]   First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial [J].
Morgan, Gareth J. ;
Davies, Faith E. ;
Gregory, Walter M. ;
Cocks, Kim ;
Bell, Sue E. ;
Szubert, Alex J. ;
Navarro-Coy, Nuria ;
Drayson, Mark T. ;
Owen, Roger G. ;
Feyler, Sylvia ;
Ashcroft, A. John ;
Ross, Fiona ;
Byrne, Jennifer ;
Roddie, Huw ;
Rudin, Claudius ;
Cook, Gordon ;
Jackson, Graham H. ;
Child, J. Anthony .
LANCET, 2010, 376 (9757) :1989-1999